StudyStudy type and ELNo. of patientsPatient characteristicsInterventionComparisonLength of follow-upOutcome measuresEffect sizeAdditional comments
Pedersen 1988418DB RCT cross-over
EL = 1−
33; 28 completed (13 women)M/F median age 66.5 years, ≥ 2 nocturia episodes (median 17.5/week)
Exclusions: urinary retention, UTI, hypo- or hyper-kalaemia, creatinine > 120 μmol/l
Bumetanide 1 mgPlacebo2×2 weeks txNocturia episodes/week10 vs 13.8; difference −3.8 (IQR −1.5, 5.5), P < 0.05Funding: none declared.
[EL = 1−] 5 pts excluded from analysis owing to protocol violations (2), adverse effects (3; indisposition, headache, stranguria).
Doses taken 4–6 h before bedtime.

From: Evidence tables for included studies

Cover of Urinary Incontinence
Urinary Incontinence: The Management of Urinary Incontinence in Women.
NICE Clinical Guidelines, No. 40.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2006 Oct.
Copyright © 2006, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.